The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen
Open accessAbstract
The growing resistance to current first-line antimalarial drugs represents a major health challenge. To facilitate the discovery of new antimalarials, we have implemented an efficient and robust high-throughput cell-based screen (1,536-well format) based on proliferation of Plasmodium falciparum (Pf) in erythrocytes. From a screen of ≈1.7 million compounds, we identified a diverse collection of ≈6,000 small molecules comprised of >530 distinct scaffolds, all of which show potent antimalarial activity (<1.25 μM). Most known antimalarials were identified in this screen, thus validating our approach. In addition, we identified many novel chemical scaffolds, which likely act through both known and novel pathways. We further show that in some cases the mechanism of action of these antimalarials can be determined by in silico compound activity profiling. This method uses large datasets from unrelated cellular and biochemical screens and the guilt-by-association principle to predict which cellular pathway and/or protein target is being inhibited by select compounds. In addition, the screening method has the potential to provide the malaria community with many new starting points for the development of biological probes and drugs with novel antiparasitic activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique
Desjardins, R. E., Canfield, C. J., Haynes, J. D., & Chulay, J. D. (1979) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.16.6.710 · Cited by 2,514
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening
Smilkstein, M., Sriwilaijaroen, N., Kelly, J. X., Wilairat, P., & Riscoe, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1803-1806.2004 · Cited by 1,210
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Genomic profiling of drug sensitivities via induced haploinsufficiency
Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H., Winzeler, E. A., Astromoff, A., & Davis, R. W. (1999) · Nature Genetics · doi:10.1038/6791 · Cited by 570
Self-citationMechanisms of Resistance of Malaria Parasites to Antifolates
Gregson, A., & Plowe, C. V. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.4 · Cited by 499
Insights into antifolate resistance from malarial DHFR-TS structures
Yuvaniyama, J., Chitnumsub, P., Kamchonwongpaisan, S., Vanichtanankul, J., Sirawaraporn, W., Taylor, P., Walkinshaw, M. D., & Yuthavong, Y. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb921 · Cited by 451
Johnson, J. D., Dennull, R. A., Gerena, L., Lopez-Sanchez, M., Roncal, N. E., & Waters, N. C. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01607-06 · Cited by 360
Liu, J., Istvan, E. S., Gluzman, I. Y., Gross, J., & Goldberg, D. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601876103 · Cited by 344
Cited by
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., et al. (2010) · Science · doi:10.1126/science.1193225 · Cited by 1,206
Self-citationTarget identification and mechanism of action in chemical biology and drug discovery
Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1199 · Cited by 1,096
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4683 · Cited by 607
Chemical genetics of Plasmodium falciparum
Guiguemde, W. A., Shelat, A. A., Bouck, D., Duffy, S., Crowther, G. J., Davis, P. H., Smithson, D. C., Connelly, M., Clark, J., Zhu, F., et al. (2010) · Nature · doi:10.1038/nature09099 · Cited by 566
Winter, R., Montanari, F., Noé, F., & Clevert, D.-A. (2019) · Chemical Science · doi:10.1039/c8sc04175j · Cited by 510
Identification of Small Molecule Activators of Cryptochrome
Hirota, T., Lee, J. W., St. John, P. C., Sawa, M., Iwaisako, K., Noguchi, T., Pongsawakul, P. Y., Sonntag, T., Welsh, D. K., Brenner, D. A., et al. (2012) · Science · doi:10.1126/science.1223710 · Cited by 499
Self-citationThe past, present and future of anti-malarial medicines
Tse, E. G., Korsik, M., & Todd, M. H. (2019) · Malaria Journal · doi:10.1186/s12936-019-2724-z · Cited by 471
Yeung, B. K. S., Zou, B., Rottmann, M., Lakshminarayana, S. B., Ang, S. H., Leong, S. Y., Tan, J., Wong, J., Keller-Maerki, S., Fischli, C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100410f · Cited by 432
Self-citationTargeting Plasmodium PI(4)K to eliminate malaria
McNamara, C. W., Lee, M. C. S., Lim, C. S., Lim, S. H., Roland, J., Nagle, A., Simon, O., Yeung, B. K. S., Chatterjee, A. K., McCormack, S. L., et al. (2013) · Nature · doi:10.1038/nature12782 · Cited by 431
Self-citationHalofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase
Keller, T. L., Zocco, D., Sundrud, M. S., Hendrick, M., Edenius, M., Yum, J., Kim, Y.-J., Lee, H.-K., Cortese, J. F., Wirth, D. F., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.790 · Cited by 394
Lyssiotis, C. A., Foreman, R. K., Staerk, J., Garcia, M., Mathur, D., Markoulaki, S., Hanna, J., Lairson, L. L., Charette, B. D., Bouchez, L. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903860106 · Cited by 367
Self-citationImaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery
Meister, S., Plouffe, D. M., Kuhen, K. L., Bonamy, G. M. C., Wu, T., Barnes, S. W., Bopp, S. E., Borboa, R., Bright, A. T., Che, J., et al. (2011) · Science · doi:10.1126/science.1211936 · Cited by 338
Self-citationAntimalarial drug discovery — approaches and progress towards new medicines
Flannery, E. L., Chatterjee, A. K., & Winzeler, E. A. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3138 · Cited by 313
Self-citationNew medicines to improve control and contribute to the eradication of malaria
Wells, T. N. C., Alonso, P. L., & Gutteridge, W. E. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2972 · Cited by 298
Tewari, R., Straschil, U., Bateman, A., Böhme, U., Cherevach, I., Gong, P., Pain, A., & Billker, O. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.09.006 · Cited by 297
Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., et al. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.05.011 · Cited by 287
Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination
Wells, T. N. C., Burrows, J. N., & Baird, J. K. (2010) · Trends in Parasitology · doi:10.1016/j.pt.2009.12.005 · Cited by 262
Priming the antimalarial pipeline
Fidock, D. A. (2010) · Nature · doi:10.1038/465297a · Cited by 116
Qiu, D., Pei, J. V., Rosling, J. E. O., Thathy, V., Li, D., Xue, Y., Tanner, J. D., Penington, J. S., Aw, Y. T. V., Aw, J. Y. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33403-9 · Cited by 70
High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need
Hughes, R. E., Elliott, R. J. R., Dawson, J. C., & Carragher, N. O. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.02.015 · Cited by 62
The opportunities of mining historical and collective data in drug discovery
Wassermann, A. M., Lounkine, E., Davies, J. W., Glick, M., & Camargo, L. M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.11.004 · Cited by 34
Metadata
- Authors
- Plouffe, D., Brinker, A., McNamara, C., Henson, K., Kato, N., Kuhen, K., Nagle, A., Adrián, F., Matzen, J. T., Anderson, P., Nam, T.-G., Gray, N. S., Chatterjee, A., Janes, J., Yan, S. F., Trager, R., Caldwell, J. S., Schultz, P. G., Zhou, Y., & Winzeler, E. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-07
- Volume
- 105
- Issue
- 26
- Pages
- 9059-9064
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2106374535
- Cited by
- 449
- References
- 21
- FWCI
- 26.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.